{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:11:00Z","timestamp":1791810660844,"version":"4.3.4"},"reference-count":47,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,5,4]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the long-term sustainability of response to the Janus kinase inhibitor upadacitinib among patients with rheumatoid arthritis and an inadequate response or intolerance to biological disease-modifying antirheumatic drugs (bDMARD-IR) in the SELECT-BEYOND phase 3 trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients on background conventional synthetic DMARDs (csDMARDs) were treated once daily with upadacitinib 15\u2009mg or placebo. Patients who completed the week 24 visit could enter a long-term extension of up to 5 years. The sustainability of response was assessed based on achievement of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28-joint count using C-reactive protein (DAS28 (CRP)) targets and evaluated up to week 260 in all patients receiving the approved upadacitinib 15\u2009mg dose, including those randomised to upadacitinib 15\u2009mg and those who switched from placebo to upadacitinib 15\u2009mg at week 12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this bDMARD-IR population, 45% (n=104\/229) and 79% (n=172\/219) of patients treated with upadacitinib 15\u2009mg plus background csDMARD(s) achieved CDAI remission or CDAI low disease activity (LDA) at any point during the 5-year study, respectively. Of those who achieved CDAI remission\/LDA, 25%\/43% maintained their initial response through 240 weeks of follow-up after first achieving response. Most patients who lost remission or LDA were able to recapture that response by the cut-off date. Similar overall results were observed for SDAI and DAS28 (CRP). No strong predictors of response were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Over three-quarters of bDMARD-IR patients achieved CDAI LDA with upadacitinib, and almost half of those maintained LDA through 240 weeks of follow-up. Remission was achieved by nearly half of all patients and maintained in approximately a quarter of those achieving remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02706847\">NCT02706847<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-004037","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T03:00:36Z","timestamp":1721876436000},"page":"e004037","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02706847","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02706847","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"first","affiliation":[{"name":"Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hall","sequence":"additional","affiliation":[{"name":"Rheumatology, Emeritus Research and Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin F","family":"Wells","sequence":"additional","affiliation":[{"name":"Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Meerwein","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oishi","family":"Tanjinatus","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"2025090313005697000_10.3.e004037.1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol Int"},{"key":"2025090313005697000_10.3.e004037.2","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025090313005697000_10.3.e004037.3","doi-asserted-by":"crossref","unstructured":"World Health Organization . The global burden of disease: 2004 update. 2004. doi:10.1016\/S0262-1762(04)00135-X","DOI":"10.1016\/S0262-1762(04)00135-X"},{"key":"2025090313005697000_10.3.e004037.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090313005697000_10.3.e004037.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2025090313005697000_10.3.e004037.6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/acr.20021","article-title":"Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review","volume":"62","author":"van Tuyl","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313005697000_10.3.e004037.7","doi-asserted-by":"crossref","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2025090313005697000_10.3.e004037.8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313005697000_10.3.e004037.9","first-page":"4","article-title":"Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence","volume":"81","author":"Cohen","year":"2008","journal-title":"J Rheumatol Suppl"},{"key":"2025090313005697000_10.3.e004037.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.026"},{"key":"2025090313005697000_10.3.e004037.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0707-1","article-title":"Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now","volume":"17","author":"Nagy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313005697000_10.3.e004037.12","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis","volume":"3","author":"Singh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090313005697000_10.3.e004037.13","first-page":"S33","article-title":"Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target","volume":"71 Suppl 1","author":"Pincus","year":"2013","journal-title":"Bull Hosp Jt Dis (2013)"},{"key":"2025090313005697000_10.3.e004037.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2025090313005697000_10.3.e004037.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2025090313005697000_10.3.e004037.16","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313005697000_10.3.e004037.17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of Upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090313005697000_10.3.e004037.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2025090313005697000_10.3.e004037.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2025090313005697000_10.3.e004037.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313005697000_10.3.e004037.21","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313005697000_10.3.e004037.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2025090313005697000_10.3.e004037.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2025090313005697000_10.3.e004037.24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care & Research"},{"key":"2025090313005697000_10.3.e004037.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224742"},{"key":"2025090313005697000_10.3.e004037.26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/rheumatology\/kez461","article-title":"Remission vs low disease activity: function, quality of life and structural outcomes in the early rheumatoid arthritis study and network","volume":"59","author":"Nikiphorou","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313005697000_10.3.e004037.27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/rheumatology\/key108","article-title":"Is remission achievable in most patients with rheumatoid arthritis? Results suggest not","volume":"58","author":"Bukhari","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313005697000_10.3.e004037.28","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X17720366"},{"key":"2025090313005697000_10.3.e004037.29","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211002682","article-title":"Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis","volume":"13","author":"Migliore","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090313005697000_10.3.e004037.30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/13696998.2016.1275653","article-title":"Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis","volume":"20","author":"Chastek","year":"2017","journal-title":"J Med Econ"},{"key":"2025090313005697000_10.3.e004037.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218419"},{"key":"2025090313005697000_10.3.e004037.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206411"},{"key":"2025090313005697000_10.3.e004037.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204531"},{"key":"2025090313005697000_10.3.e004037.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090313005697000_10.3.e004037.35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030509","article-title":"The key comorbidities in patients with rheumatoid arthritis: a narrative review","volume":"10","author":"Taylor","year":"2021","journal-title":"J Clin Med"},{"key":"2025090313005697000_10.3.e004037.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223050"},{"key":"2025090313005697000_10.3.e004037.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0928-y","article-title":"Co-morbidity in patients with early rheumatoid arthritis - inflammation matters","volume":"18","author":"Innala","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313005697000_10.3.e004037.38","doi-asserted-by":"crossref","first-page":"ard","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090313005697000_10.3.e004037.39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003918","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study","volume":"10","author":"Fleischmann","year":"2024","journal-title":"RMD Open"},{"key":"2025090313005697000_10.3.e004037.40","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"2025090313005697000_10.3.e004037.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090313005697000_10.3.e004037.42","first-page":"84","article-title":"Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis","volume":"9","author":"Louder","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"2025090313005697000_10.3.e004037.43","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/PPA.S117774","article-title":"Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach","volume":"10","author":"Alten","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2025090313005697000_10.3.e004037.44","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1007\/s12325-023-02619-6","article-title":"One-year medication adherence and persistence in rheumatoid arthritis in clinical practice: a retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib","volume":"40","author":"Bergman","year":"2023","journal-title":"Adv Ther"},{"key":"2025090313005697000_10.3.e004037.45","doi-asserted-by":"crossref","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","article-title":"Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents","volume":"18","author":"Rubbert-Roth","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025090313005697000_10.3.e004037.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.2137"},{"key":"2025090313005697000_10.3.e004037.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220973"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-004037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:01:05Z","timestamp":1756929665000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-004037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,24]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/rmdopen-2023-004037"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-004037","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}